Skye Bioscience, Inc.
SKYENasdaq
$0.65
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↓ -82.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.8M
Enterprise Value
$8.7M
P/E
—
P/S
—
P/B
2.9
EV/EBITDA
—
PEG
—
FCF Yield
-164.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$57.3M
Free Cash Flow (TTM)
-$42.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-636.2%
ROIC
—
Debt / Equity
—
Net Cash
$17.1M
Return 1Y
-82.5%
Company profile
Skye Bioscience, Inc. discovers, develops, and commercializes cannabinoid-based molecules. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.
- CEO
- Punit S. Dhillon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 11
- Headquarters
- California
- Website
- skyebioscience.com
Earnings
SKYE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.32↑ +14.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.3M | -$7.8M | -$18.3M | -$34.7M | -$30.2M | -$58.2M |
| Net income | -$6.6M | -$8.5M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| Diluted EPS | -$0.03 | -$0.02 | -$8.77 | -$5.37 | -$0.73 | -$1.41 |
| Operating cash flow | -$6.1M | -$6.5M | -$12.7M | -$14.0M | -$25.2M | -$43.1M |
| Free cash flow | -$6.1M | -$6.6M | -$12.8M | -$14.0M | -$26.8M | -$43.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.4M | -$5.0M | -$10.7M | -$11.8M | -$18.2M | -$13.3M | -$14.9M | -$12.7M |
| Net income | -$7.9M | -$3.9M | -$9.7M | -$11.1M | -$17.6M | -$12.8M | -$14.4M | -$12.5M |
| Diluted EPS | -$0.20 | -$0.10 | -$0.25 | -$0.28 | -$0.44 | -$0.32 | -$0.37 | -$0.32 |
| Operating cash flow | -$7.1M | -$5.3M | -$8.2M | -$9.2M | -$10.7M | -$13.4M | -$9.8M | -$8.6M |
| Free cash flow | -$7.1M | -$6.8M | -$8.2M | -$9.2M | -$10.7M | -$13.4M | -$9.8M | -$8.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-22 | Schwab Andrew J. | Sale | 163,979 | $3.42 | $560,808.18 | filing |
| 2025-08-22 | 5AM Partners VII, LLC | Sale | 163,979 | $3.42 | $560,808.18 | filing |
| 2025-08-22 | Schwab Andrew J. | Sale | 6,470 | $3.42 | $22,127.40 | filing |
| 2025-08-22 | 5AM Partners VII, LLC | Sale | 6,470 | $3.42 | $22,127.40 | filing |
| 2025-08-21 | Schwab Andrew J. | Sale | 58,642 | $3.57 | $209,351.94 | filing |
| 2025-08-21 | 5AM Partners VII, LLC | Sale | 58,642 | $3.57 | $209,351.94 | filing |
| 2025-08-21 | 5AM Partners VII, LLC | Sale | 2,314 | $3.57 | $8,260.98 | filing |
| 2025-08-21 | Schwab Andrew J. | Sale | 2,314 | $3.57 | $8,260.98 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.